David Hall

1.9k total citations
30 papers, 846 citations indexed

About

David Hall is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, David Hall has authored 30 papers receiving a total of 846 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in David Hall's work include Sarcoma Diagnosis and Treatment (13 papers), Neuroblastoma Research and Treatments (6 papers) and Acute Myeloid Leukemia Research (3 papers). David Hall is often cited by papers focused on Sarcoma Diagnosis and Treatment (13 papers), Neuroblastoma Research and Treatments (6 papers) and Acute Myeloid Leukemia Research (3 papers). David Hall collaborates with scholars based in United States, Switzerland and Australia. David Hall's co-authors include Louis Lippiello, Henry J. Mankin, Elizabeth Fox, Donald A. Barkauskas, Brenda J. Weigel, Noralane M. Lindor, Steve Gallinger, Allyson Templeton, Loı̈c Le Marchand and Jeremy R. Jass and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

David Hall

29 papers receiving 818 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Hall United States	14	261	244	206	196	161	30	846
Ming‐Han Chen Taiwan	20	199 0.8×	346 1.4×	268 1.3×	89 0.5×	118 0.7×	66	1.1k
Elvis Terci Valera Brazil	18	275 1.1×	725 3.0×	69 0.3×	118 0.6×	186 1.2×	108	1.4k
Jennifer A. Bennett United States	20	184 0.7×	247 1.0×	199 1.0×	124 0.6×	51 0.3×	79	1.0k
Lizet E. van der Kolk Netherlands	17	322 1.2×	308 1.3×	68 0.3×	337 1.7×	146 0.9×	33	1.3k
Qi Zhu China	20	328 1.3×	259 1.1×	41 0.2×	76 0.4×	89 0.6×	59	1.0k
Victoria Bedell United States	16	181 0.7×	431 1.8×	54 0.3×	111 0.6×	79 0.5×	40	1.0k
Takeo Isozaki Japan	20	312 1.2×	244 1.0×	363 1.8×	54 0.3×	82 0.5×	55	930
Susanne Timshel Denmark	15	281 1.1×	343 1.4×	44 0.2×	202 1.0×	364 2.3×	20	1.1k
D. Carrle Germany	8	215 0.8×	255 1.0×	244 1.2×	65 0.3×	162 1.0×	8	832
Marie Jarošová Czechia	17	136 0.5×	264 1.1×	84 0.4×	156 0.8×	88 0.5×	87	766

Countries citing papers authored by David Hall

Since Specialization

Citations

This map shows the geographic impact of David Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hall more than expected).

Fields of papers citing papers by David Hall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hall. The network helps show where David Hall may publish in the future.

Co-authorship network of co-authors of David Hall

This figure shows the co-authorship network connecting the top 25 collaborators of David Hall. A scholar is included among the top collaborators of David Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hall. David Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stieglitz, Elliot, Alex G. Lee, Steven P. Angus, et al.. (2024). Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group. Cancer Discovery. 14(9). 1590–1598. 4 indexed citations

Laetsch, Theodore W., Stephan D. Voss, Kathleen Ludwig, et al.. (2024). Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823). Journal of Clinical Oncology. 43(10). 1188–1197. 4 indexed citations

Hersh, Deborah, et al.. (2023). Seeing Voices: A Dynamic, Interprofessional Approach to Teaching Performing Arts and Speech-Language Pathology Students About Vocal Anatomy and Physiology. Journal of Voice. 40(2). 350–359.

Abbou, Samuel, Kelly Klega, Junko Tsuji, et al.. (2023). Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 41(13). 2382–2393. 16 indexed citations

Stieglitz, Elliot, Alex Lee, Steven P. Angus, et al.. (2023). Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group. Blood. 142(Supplement 1). 74–74. 2 indexed citations

Wedekind, Mary Frances, Srivandana Akshintala, Brigitte C. Widemann, et al.. (2023). Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.. Journal of Clinical Oncology. 41(16_suppl). TPS10066–TPS10066. 1 indexed citations

Piquette, Dominique, et al.. (2023). Critical Care Education and the ICU Care Continuum. American Journal of Respiratory and Critical Care Medicine. 209(4). 360–361. 1 indexed citations

Laetsch, Theodore W., Kathleen Ludwig, David Hall, et al.. (2023). Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.. Journal of Clinical Oncology. 41(16_suppl). 10008–10008. 4 indexed citations

Shulman, David S., Sonja Chen, David Hall, et al.. (2022). Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children’s Oncology Group. British Journal of Cancer. 127(12). 2220–2226. 13 indexed citations

10.

Foster, Jennifer H., Stephan D. Voss, David Hall, et al.. (2021). Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clinical Cancer Research. 27(13). 3543–3548. 61 indexed citations

11.

Skolnik, Jeffrey, David Hall, Donald A. Barkauskas, et al.. (2021). Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1. Cancer Chemotherapy and Pharmacology. 88(2). 359–365. 7 indexed citations

12.

Gill, Jonathan, Michael Roth, Richard Görlick, et al.. (2021). Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma. 2021. 1–10. 9 indexed citations

13.

Geller, James I., Joseph G. Pressey, Malcolm A. Smith, et al.. (2020). ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study. Cancer. 126(24). 5303–5310. 30 indexed citations

14.

Hingorani, Pooja, Valentin Dinu, Xiyuan Zhang, et al.. (2020). Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children’s Oncology Group. Scientific Reports. 10(1). 12318–12318. 25 indexed citations

15.

Mossé, Yaël P., Elizabeth Fox, David T. Teachey, et al.. (2019). A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clinical Cancer Research. 25(11). 3229–3238. 79 indexed citations

16.

Kopp, Lisa M., Richard B. Womer, Cindy L. Schwartz, et al.. (2019). Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group. Cardio-Oncology. 5(1). 15–15. 28 indexed citations

17.

Patidar, Rajesh, Young Song, Ashley Walton, et al.. (2018). Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children’s Oncology Group, the Children’s Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.. Journal of Clinical Oncology. 36(15_suppl). 10515–10515. 7 indexed citations

18.

Glover, Jason, Tsz‐Kwong Man, Donald A. Barkauskas, et al.. (2017). Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. PLoS ONE. 12(7). e0181204–e0181204. 4 indexed citations

19.

Hall, David, et al.. (2006). Contrasting signal transduction mechanisms in bacterial and eukaryotic gene transcription. FEMS Microbiology Letters. 261(2). 155–164. 28 indexed citations

20.

Hall, David. (1981). Patterns of Time in Hospital Life. Sociology. 15(1). 158–159. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact